You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDextroamphetamine
Accession NumberDB01576
TypeSmall Molecule
GroupsApproved, Illicit
Description

Dextroamphetamine is the dextrorotary stereoisomer of the amphetamine molecule, which can take two different forms. It is a slightly polar, weak base and is lipophilic.

Structure
Thumb
Synonyms
SynonymLanguageCode
(+)-(S)-amphetamineNot AvailableNot Available
(+)-alpha-MethylphenethylamineNot AvailableNot Available
(+)-alpha-MethylphenylethylamineNot AvailableNot Available
(+)-AmphetamineNot AvailableNot Available
(AlphaS)-alpha-methylbenzeneethanamineNot AvailableNot Available
(S)-(+)-AmphetamineNot AvailableNot Available
(S)-(+)-beta-PhenylisopropylamineNot AvailableNot Available
(S)-1-Phenyl-2-aminopropaneNot AvailableNot Available
(S)-1-Phenyl-2-propylamineNot AvailableNot Available
(S)-alpha-MethylbenzeneethanamineNot AvailableNot Available
(S)-amphetamineNot AvailableNot Available
d-amphetamineNot AvailableNot Available
dexamphetamineNot AvailableNot Available
DextroamphetamineNot AvailableNot Available
Prescription ProductsNot Available
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dextroamphetamine Sulfatetablet5 mgoralMallinckrodt, Inc.2010-02-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dextroamphetamine Sulfatetablet10 mgoralMallinckrodt, Inc.2010-02-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dextroamphetamine Sulfatetablet5 mgoralBarr Laboratories Inc.2001-02-12Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dextroamphetamine Sulfatetablet10 mgoralBarr Laboratories Inc.2001-02-12Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dextroamphetamine Sulfatecapsule, extended release5 mgoralBarr Laboratories Inc.2002-02-26Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dextroamphetamine Sulfatecapsule, extended release10 mgoralBarr Laboratories Inc.2002-02-26Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dextroamphetamine Sulfatecapsule, extended release15 mgoralBarr Laboratories Inc.2002-02-26Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dextroamphetamine Sulfatetablet5 mgoralAurolife Pharma, LLC2012-02-14Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dextroamphetamine Sulfatetablet10 mgoralAurolife Pharma, LLC2012-02-14Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Procentraliquid5 mg/5mLoralFSC Laboratories, Inc2010-08-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Procentrasolution5 mg/5mLoralIndependence Pharmaceuticals, LLC2014-05-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Zenzeditablet2.5 mgoralArbor Pharmaceuticals, Inc.2013-05-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Zenzeditablet5 mgoralArbor Pharmaceuticals, Inc.2013-05-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Zenzeditablet7.5 mgoralArbor Pharmaceuticals, Inc.2013-05-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Zenzeditablet10 mgoralArbor Pharmaceuticals, Inc.2013-05-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Zenzeditablet15 mgoralArbor Pharmaceuticals, Inc.2014-05-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Zenzeditablet20 mgoralArbor Pharmaceuticals, Inc.2014-05-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Zenzeditablet30 mgoralArbor Pharmaceuticals, Inc.2014-05-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dextroamphetaminesolution5 mg/5mLoralTris Pharma Inc2013-05-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dextroamphetamine Sulfatetablet5 mgoralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dextroamphetamine Sulfatecapsule, extended release5 mgoralActavis Pharma, Inc.2014-06-19Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dextroamphetamine Sulfatecapsule, extended release10 mgoralActavis Pharma, Inc.2014-06-19Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dextroamphetamine Sulfatecapsule, extended release15 mgoralActavis Pharma, Inc.2014-06-19Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dexedrinetablet5 mgoralAmedra Pharmaceuticals LLC2014-07-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dexedrinetablet10 mgoralAmedra Pharmaceuticals LLC2014-07-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dextroamphetamine Sulfatetablet5 mgoralWilshire Pharmaceuticals, Inc.2012-07-16Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dextroamphetamine Sulfatetablet10 mgoralWilshire Pharmaceuticals, Inc.2012-07-20Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dextroamphetamine Sulfatecapsule, extended release15 mgoralPhysicians Total Care, Inc.2005-08-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dextroamphetamine Sulfatecapsule, extended release10 mgoralPhysicians Total Care, Inc.2005-11-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dextroamphetamine Sulfatetablet5 mgoralEthex Corporation2009-11-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dextroamphetamine Sulfatetablet10 mgoralEthex Corporation2009-11-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dextroamphetamine Sulfatetablet5 mgoralCore Pharma, Llc2014-05-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dextroamphetamine Sulfatetablet10 mgoralCore Pharma, Llc2014-05-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dextroamphetamine Sulfatesolution5 mg/5mLoralTalec Pharma, LLC2014-01-06Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International Brands
NameCompany
AttentinMedice
DexamphetamineSigma
Brand mixtures
Brand NameIngredients
Adderall XRAmphetamine Aspartate Monohydrate + Amphetamine Sulfate + Dextroamphetamine Saccharate + Dextroamphetamine Sulfate
Salts
Name/CASStructureProperties
Dextroamphetamine sulfate
Thumb
  • InChI Key: SOFQDLYSFOWTJX-QRPNPIFTSA-N
  • Monoisotopic Mass: 233.072178663
  • Average Mass: 233.285
DBSALT000046
Categories
CAS number51-64-9
WeightAverage: 135.2062
Monoisotopic: 135.104799421
Chemical FormulaC9H13N
InChI KeyKWTSXDURSIMDCE-QMMMGPOBSA-N
InChI
InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3/t8-/m0/s1
IUPAC Name
(2S)-1-phenylpropan-2-amine
SMILES
C[C@H](N)CC1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenethylamines
Direct ParentAmphetamines and derivatives
Alternative Parents
Substituents
  • Amphetamine or derivatives
  • Phenylpropane
  • Aralkylamine
  • Hydrocarbon derivative
  • Primary amine
  • Organonitrogen compound
  • Primary aliphatic amine
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationUsed to treat attention deficit hyperactivity disorder (ADHD).
PharmacodynamicsAmphetamines such as dextroamphetamine are noncatecholamine, sympathomimetic amines with CNS stimulant activity. Peripheral actions include elevations of systolic and diastolic blood pressures and weak bronchodilator and respiratory stimulant action. There is neither specific evidence that clearly establishes the mechanism whereby amphetamines produce mental and behavioral effects in children, nor conclusive evidence regarding how these effects relate to the condition of the central nervous system.
Mechanism of actionThe exact mechanism of action is not known. Dextroamphetamine stimulates the release of norepinephrine from central adrenergic receptors. At higher dosages, it causes release of dopamine from the mesocorticolimbic system and the nigrostriatal dopamine systems by reversal of the monoamine transporters. Dextroamphetamine may also act as a direct agonist on central 5-HT receptors and may inhibit monoamine oxidase (MAO). In the periphery, amphetamines are believed to cause the release of noradrenaline by acting on the adrenergic nerve terminals and alpha- and beta-receptors. Modulation of serotonergic pathways may contribute to the calming affect.
AbsorptionOral bioavailability is over 75%.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationNot Available
Half life10-28 hours (average is approximately 12 hours)
ClearanceNot Available
ToxicityIn rats, the oral LD50 of dextroamphetamine sulfate is 96.8 mg/kg. Manifestations of acute overdosage with amphetamines include restlessness, tremor, hyperreflexia, rhabdomyolysis, rapid respiration, hyperpyrexia, confusion, assaultiveness, hallucinations, panic states. Fatigue and depression usually follow the central stimulation. Cardiovascular effects include arrhythmias, hypertension or hypotension, and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps. Fatal poisoning is usually preceded by convulsions and coma.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9972
Blood Brain Barrier+0.9565
Caco-2 permeable+0.8395
P-glycoprotein substrateNon-substrate0.7379
P-glycoprotein inhibitor INon-inhibitor0.9519
P-glycoprotein inhibitor IINon-inhibitor0.9859
Renal organic cation transporterNon-inhibitor0.8002
CYP450 2C9 substrateNon-substrate0.8114
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateNon-substrate0.795
CYP450 1A2 substrateNon-inhibitor0.5697
CYP450 2C9 substrateNon-inhibitor0.9313
CYP450 2D6 substrateInhibitor0.657
CYP450 2C19 substrateNon-inhibitor0.8445
CYP450 3A4 substrateNon-inhibitor0.8709
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8732
Ames testNon AMES toxic0.93
CarcinogenicityNon-carcinogens0.6869
BiodegradationNot ready biodegradable0.6575
Rat acute toxicity3.2491 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9452
hERG inhibition (predictor II)Non-inhibitor0.9231
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Capsule, extended releaseoral10 mg
Capsule, extended releaseoral15 mg
Capsule, extended releaseoral5 mg
Liquidoral5 mg/5mL
Solutionoral5 mg/5mL
Tabletoral10 mg
Tabletoral15 mg
Tabletoral2.5 mg
Tabletoral20 mg
Tabletoral30 mg
Tabletoral5 mg
Tabletoral7.5 mg
Prices
Unit descriptionCostUnit
D-amphetamine sulfate powder900.0USD g
Desoxyn 5 mg tablet5.1USD tablet
Dexedrine 15 mg 24 Hour Capsule4.22USD capsule
Dextroamphetamine Sulfate CR 15 mg 24 Hour Capsule3.47USD capsule
Dexedrine 10 mg 24 Hour Capsule3.23USD capsule
Dexedrine 5 mg 24 Hour Capsule3.0USD capsule
Dextroamphetamine Sulfate CR 10 mg 24 Hour Capsule2.96USD capsule
Dexedrine spansule 15 mg2.45USD each
Dextroamphetamine Sulfate CR 5 mg 24 Hour Capsule2.06USD capsule
Dexedrine spansule 10 mg1.91USD each
Dexedrine spansule 5 mg1.91USD each
Dexedrine 15 mg Sustained-Release Capsule1.08USD capsule
Dextroamphetamine Sulfate 10 mg tablet0.92USD tablet
Dexedrine 10 mg Sustained-Release Capsule0.89USD capsule
Dextroamphetamine Sulfate 5 mg tablet0.65USD tablet
Dexedrine 5 mg Tablet0.62USD tablet
Dextroamphetamine 10 mg tablet0.56USD tablet
Dextrostat 10 mg tablet0.48USD tablet
Dextroamphetamine 5 mg tablet0.28USD tablet
Dextrostat 5 mg tablet0.25USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point< 25 °CPhysProp
boiling point203 °CPhysProp
logP1.76SANGSTER (1994); similar isomer
pKa9.9SANGSTER (1994); similar isomer
Predicted Properties
PropertyValueSource
Water Solubility1.74 mg/mLALOGPS
logP1.85ALOGPS
logP1.8ChemAxon
logS-1.9ALOGPS
pKa (Strongest Basic)10.01ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area26.02 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity43.71 m3·mol-1ChemAxon
Polarizability16.08 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (6.85 KB)
SpectraMS
References
Synthesis Reference

Nabenhauer, F.P.; US. Patent 2,276,508; March 17,1942; assigned to Smith, Kline & French
Laboratories.

General Reference
  1. Yamada H, Baba T, Hirata Y, Oguri K, Yoshimura H: Studies on N-demethylation of methamphetamine by liver microsomes of guinea-pigs and rats: the role of flavin-containing mono-oxygenase and cytochrome P-450 systems. Xenobiotica. 1984 Nov;14(11):861-6. Pubmed
  2. Warneke L: Psychostimulants in psychiatry. Can J Psychiatry. 1990 Feb;35(1):3-10. Pubmed
  3. Wagner GJ, Rabkin R: Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2000 Jun;61(6):436-40. Pubmed
  4. Martinsson L, Yang X, Beck O, Wahlgren NG, Eksborg S: Pharmacokinetics of dexamphetamine in acute stroke. Clin Neuropharmacol. 2003 Sep-Oct;26(5):270-6. Pubmed
  5. Butefisch CM, Davis BC, Sawaki L, Waldvogel D, Classen J, Kopylev L, Cohen LG: Modulation of use-dependent plasticity by d-amphetamine. Ann Neurol. 2002 Jan;51(1):59-68. Pubmed
External Links
ATC CodesNot Available
AHFS Codes
  • 28:20.04
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AcebutololMay enhance the adverse/toxic effect of other Sympathomimetics.
AcepromazineMay diminish the stimulatory effect of Amphetamines.
AcetazolamideMay decrease the excretion of Amphetamines. Exceptions: Brinzolamide; Dorzolamide.
AcetophenazineMay diminish the stimulatory effect of Amphetamines.
Aluminum hydroxideMay decrease the excretion of Amphetamines.
AmisulprideMay diminish the stimulatory effect of Amphetamines.
Ammonium chlorideMay decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.
AmphetamineMay enhance the adverse/toxic effect of other Sympathomimetics.
AripiprazoleMay diminish the stimulatory effect of Amphetamines.
AtomoxetineMay enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.
BenzphetamineMay enhance the adverse/toxic effect of other Sympathomimetics.
BenzquinamideMay diminish the stimulatory effect of Amphetamines.
Calcium carbonateMay decrease the excretion of Amphetamines.
CarphenazineMay diminish the stimulatory effect of Amphetamines.
ChlormezanoneMay diminish the stimulatory effect of Amphetamines.
ChlorphentermineMay enhance the adverse/toxic effect of other Sympathomimetics.
ChlorpromazineMay diminish the stimulatory effect of Amphetamines.
ChlorprothixeneMay diminish the stimulatory effect of Amphetamines.
ClenbuterolMay enhance the adverse/toxic effect of other Sympathomimetics.
ClozapineMay diminish the stimulatory effect of Amphetamines.
DiclofenamideMay decrease the excretion of Amphetamines. Exceptions: Brinzolamide; Dorzolamide.
DobutamineMay enhance the adverse/toxic effect of other Sympathomimetics.
DopamineMay enhance the adverse/toxic effect of other Sympathomimetics.
DroperidolMay diminish the stimulatory effect of Amphetamines.
EpinephrineMay enhance the adverse/toxic effect of other Sympathomimetics.
EsomeprazoleProton Pump Inhibitors may increase the absorption of Dextroamphetamine. Specifically, the dextroamphetamine absorption rate from mixed amphetamine salt extended release (XR) capsules may be increased in the first hours after dosing.
EthosuximideAmphetamines may diminish the therapeutic effect of Ethosuximide. Amphetamines may decrease the serum concentration of Ethosuximide.
EthoxzolamideMay decrease the excretion of Amphetamines. Exceptions: Brinzolamide; Dorzolamide.
FencamfamineMay diminish the stimulatory effect of Amphetamines.
FenoterolMay enhance the adverse/toxic effect of other Sympathomimetics.
FlupentixolMay diminish the stimulatory effect of Amphetamines.
FluphenazineMay diminish the stimulatory effect of Amphetamines.
FluspirileneMay diminish the stimulatory effect of Amphetamines.
FormoterolMay enhance the adverse/toxic effect of other Sympathomimetics.
HaloperidolMay diminish the stimulatory effect of Amphetamines.
Ioflupane I 123Amphetamines may diminish the diagnostic effect of Ioflupane I 123.
IsoprenalineMay enhance the adverse/toxic effect of other Sympathomimetics.
LabetalolMay enhance the adverse/toxic effect of other Sympathomimetics.
LansoprazoleProton Pump Inhibitors may increase the absorption of Dextroamphetamine. Specifically, the dextroamphetamine absorption rate from mixed amphetamine salt extended release (XR) capsules may be increased in the first hours after dosing.
LinezolidMay enhance the hypertensive effect of Sympathomimetics.
LithiumMay diminish the stimulatory effect of Amphetamines.
LoxapineMay diminish the stimulatory effect of Amphetamines.
Magnesium oxideMay decrease the excretion of Amphetamines.
MephentermineMay enhance the adverse/toxic effect of other Sympathomimetics.
MesoridazineMay diminish the stimulatory effect of Amphetamines.
MetaraminolMay enhance the adverse/toxic effect of other Sympathomimetics.
MethamphetamineMay enhance the adverse/toxic effect of other Sympathomimetics.
MethotrimeprazineMay diminish the stimulatory effect of Amphetamines.
MethoxamineMay enhance the adverse/toxic effect of other Sympathomimetics.
MidodrineMay enhance the adverse/toxic effect of other Sympathomimetics.
MolindoneMay diminish the stimulatory effect of Amphetamines.
NaphazolineMay enhance the adverse/toxic effect of other Sympathomimetics.
NorepinephrineMay enhance the adverse/toxic effect of other Sympathomimetics.
OlanzapineMay diminish the stimulatory effect of Amphetamines.
OmeprazoleProton Pump Inhibitors may increase the absorption of Dextroamphetamine. Specifically, the dextroamphetamine absorption rate from mixed amphetamine salt extended release (XR) capsules may be increased in the first hours after dosing.
OndansetronMay diminish the stimulatory effect of Amphetamines.
OrciprenalineMay enhance the adverse/toxic effect of other Sympathomimetics.
OxymetazolineMay enhance the adverse/toxic effect of other Sympathomimetics.
PaliperidoneMay diminish the stimulatory effect of Amphetamines.
PantoprazoleProton Pump Inhibitors may increase the absorption of Dextroamphetamine. Specifically, the dextroamphetamine absorption rate from mixed amphetamine salt extended release (XR) capsules may be increased in the first hours after dosing.
PerphenazineMay diminish the stimulatory effect of Amphetamines.
PhenmetrazineMay enhance the adverse/toxic effect of other Sympathomimetics.
PhenobarbitalAmphetamines may decrease the serum concentration of PHENobarbital.
PhentermineMay enhance the adverse/toxic effect of other Sympathomimetics.
PhenylephrineMay enhance the adverse/toxic effect of other Sympathomimetics.
PhenylpropanolamineMay enhance the adverse/toxic effect of other Sympathomimetics.
PhenytoinAmphetamines may decrease the serum concentration of Phenytoin.
PimozideMay diminish the stimulatory effect of Amphetamines.
PiperacetazineMay diminish the stimulatory effect of Amphetamines.
ProchlorperazineMay diminish the stimulatory effect of Amphetamines.
PromazineMay diminish the stimulatory effect of Amphetamines.
QuetiapineMay diminish the stimulatory effect of Amphetamines.
RabeprazoleProton Pump Inhibitors may increase the absorption of Dextroamphetamine. Specifically, the dextroamphetamine absorption rate from mixed amphetamine salt extended release (XR) capsules may be increased in the first hours after dosing.
RemoxiprideMay diminish the stimulatory effect of Amphetamines.
ReserpineMay diminish the stimulatory effect of Amphetamines.
RisperidoneMay diminish the stimulatory effect of Amphetamines.
RitodrineMay enhance the adverse/toxic effect of other Sympathomimetics.
SalmeterolMay enhance the adverse/toxic effect of other Sympathomimetics.
SertindoleMay diminish the stimulatory effect of Amphetamines.
SulpirideMay diminish the stimulatory effect of Amphetamines.
TerbutalineMay enhance the adverse/toxic effect of other Sympathomimetics.
ThioridazineMay diminish the stimulatory effect of Amphetamines.
ThiothixeneMay diminish the stimulatory effect of Amphetamines.
TrifluoperazineMay diminish the stimulatory effect of Amphetamines.
TriflupromazineMay diminish the stimulatory effect of Amphetamines.
Vitamin CMay decrease the serum concentration of Amphetamines.
ZiprasidoneMay diminish the stimulatory effect of Amphetamines.
ZuclopenthixolMay diminish the stimulatory effect of Amphetamines.
Food InteractionsNot Available

Targets

1. Synaptic vesicular amine transporter

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: inducer

Components

Name UniProt ID Details
Synaptic vesicular amine transporter Q05940 Details

References:

  1. Sulzer D, Chen TK, Lau YY, Kristensen H, Rayport S, Ewing A: Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci. 1995 May;15(5 Pt 2):4102-8. Pubmed
  2. Sulzer D, Sonders MS, Poulsen NW, Galli A: Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol. 2005 Apr;75(6):406-33. Pubmed

2. Sodium-dependent noradrenaline transporter

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: negative modulator

Components

Name UniProt ID Details
Sodium-dependent noradrenaline transporter P23975 Details

References:

  1. Dlugos A, Freitag C, Hohoff C, McDonald J, Cook EH, Deckert J, de Wit H: Norepinephrine transporter gene variation modulates acute response to D-amphetamine. Biol Psychiatry. 2007 Jun 1;61(11):1296-305. Epub 2007 Jan 17. Pubmed
  2. Dlugos AM, Hamidovic A, Palmer AA, de Wit H: Further evidence of association between amphetamine response and SLC6A2 gene variants. Psychopharmacology (Berl). 2009 Oct;206(3):501-11. Pubmed
  3. Burnette WB, Bailey MD, Kukoyi S, Blakely RD, Trowbridge CG, Justice JB Jr: Human norepinephrine transporter kinetics using rotating disk electrode voltammetry. Anal Chem. 1996 Sep 1;68(17):2932-8. Pubmed

3. Sodium-dependent dopamine transporter

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: negative modulator

Components

Name UniProt ID Details
Sodium-dependent dopamine transporter Q01959 Details

References:

  1. Zhen J, Chen N, Reith ME: Differences in interactions with the dopamine transporter as revealed by diminishment of Na(+) gradient and membrane potential: dopamine versus other substrates. Neuropharmacology. 2005 Nov;49(6):769-79. Epub 2005 Aug 24. Pubmed
  2. Kuczenski R, Segal DS, Cho AK, Melega W: Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J Neurosci. 1995 Feb;15(2):1308-17. Pubmed
  3. Rothman RB, Dersch CM, Ananthan S, Partilla JS: Studies of the biogenic amine transporters. 13. Identification of “agonist” and “antagonist” allosteric modulators of amphetamine-induced dopamine release. J Pharmacol Exp Ther. 2009 May;329(2):718-28. Epub 2009 Feb 24. Pubmed

4. Trace amine-associated receptor 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: agonist

Components

Name UniProt ID Details
Trace amine-associated receptor 1 Q96RJ0 Details

References:

  1. Reese EA, Bunzow JR, Arttamangkul S, Sonders MS, Grandy DK: Trace amine-associated receptor 1 displays species-dependent stereoselectivity for isomers of methamphetamine, amphetamine, and para-hydroxyamphetamine. J Pharmacol Exp Ther. 2007 Apr;321(1):178-86. Epub 2007 Jan 11. Pubmed
  2. Xie Z, Westmoreland SV, Bahn ME, Chen GL, Yang H, Vallender EJ, Yao WD, Madras BK, Miller GM: Rhesus monkey trace amine-associated receptor 1 signaling: enhancement by monoamine transporters and attenuation by the D2 autoreceptor in vitro. J Pharmacol Exp Ther. 2007 Apr;321(1):116-27. Epub 2007 Jan 18. Pubmed
  3. Wolinsky TD, Swanson CJ, Smith KE, Zhong H, Borowsky B, Seeman P, Branchek T, Gerald CP: The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia. Genes Brain Behav. 2007 Oct;6(7):628-39. Epub 2006 Dec 21. Pubmed
  4. Xie Z, Miller GM: Trace amine-associated receptor 1 is a modulator of the dopamine transporter. J Pharmacol Exp Ther. 2007 Apr;321(1):128-36. Epub 2007 Jan 18. Pubmed
  5. Miller GM, Verrico CD, Jassen A, Konar M, Yang H, Panas H, Bahn M, Johnson R, Madras BK: Primate trace amine receptor 1 modulation by the dopamine transporter. J Pharmacol Exp Ther. 2005 Jun;313(3):983-94. Epub 2005 Mar 11. Pubmed

5. Alpha-1A adrenergic receptor

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Alpha-1A adrenergic receptor P35348 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

6. Alpha-1B adrenergic receptor

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
Alpha-1B adrenergic receptor P35368 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

Enzymes

1. Cytochrome P450 2D6

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2D6 P10635 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Comments
comments powered by Disqus
Drug created on August 29, 2007 08:50 / Updated on April 10, 2014 14:08